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"1043-111 Dual-Site or Bi-Atrial Pacing Does Not Enhance Atrial 
Activation as Compared to Pacing From Novel Single 
Right Atr ia l  Sites in Humans 
Kevin R. Camobell. Jeffrey M. Whitehill, Aaron Hesselson, Peter Gallagher, Tristram D. 
Bahnson, Duke University Durham, North Carolina. 
Introduction: Atrial based pacing for prevention of atrial fibrillation using standard and 
novel pacing configurations is under investigation. A possible anti-arrhythmic mechanism 
of pacing is to enhance bi-atrial activation and decrease dispersion of refractoriness. To 
determine whether dual site pacing (pacing from the distal right atdal (RA) appendage 
plus coronary sinus os), or bi-atrial pacing (pacing from the distal RA appendage plus 
distal coronary sinus) results in shortened atdal activation time (AAT) as compared to 
pacing from single RA sites, 19 patients (age 50±19 y) undergoing standard catheter 
ablation procedures were studied. 
Methods: Pacing at 600 ms was accomplished in each subject from the proximal RA 
appendage, distal RA appendage, high RA septum, coronary sinus os, and using dual 
site and bi-atdal pacing. AAT was assessed by measuring P-wave duration from high- 
resolution (50-400 mrn/s; 1-5 mV/cm) 12-lead rhythm stdps. 
Results: AAT dudng sinus rhythm (116.7±13.2 ms, mean±S.D.), and during single site 
pacing from the high septum (118.1±13.3), proximal appendage (116.4±11.2), coronary 
sinus os (118.9±15.9), and using dual site (110±12.8) or bi-atrial (107.9±14.1) pacing 
was the same (ANOVA, p>0.07). AAT during pacing from the distal RA appendage 
(129.4±21.6) was significantly greater than with pacing from any other site (ANOVA, 
p=0.001, T-test P=0.01). Dual site or bi-atdal pacing did not result in significantly shorter 
atrial activation times compared with pacing from the 'best' single site (P=0.54, 0.22 
respectively). 
Conclusions: 1) There is no significant enhancement of AAT using multi-site pacing in 
these individuals with normal intra- and inter-atrial conduction compared to RA pacing 
from a single site that yields rapid atrial activation. 2) A map-guided single RA pacing site 
can provide the benefits of muiti-sita pacing on atrial activation in such individuals without 
the need for multiple RA pacing leads. 3) Further studies are required to determine 
whether multi-site pacing provides added antiarrhythmic benefit compared to pacing from 
selected single RA pacing sites in individuals with atrial fibrillation and intact atrial con- 
duction. 
1043-111A Mult ie i te  or  Septal  Pacing for Arrhythmla Suppression 
in an Exper imenta l  Model  o f  Paroxysmal  Atr ia l  
F ibr i l lat ion? 
Ruedioer Becker. Alexander Bauer, Julia C. Senges, Frederik Voss, Wolfgang Schoels, 
University of Heidelberg, Heidelberg, Germany 
Methods: To investigate whether multisite and septal pacing suppress paroxysmal atdal 
fibrillation (AF) in an expedmental model, sterile right atrial pericarditis was induced in 12 
foxhounds to provide an anatomical substrate. As a trigger mechanism, atdal extrasysto- 
les were simulated by constant asynchronous pacing at a cycle length (CL) of 1000 ms 
from randomly selected dght or left atrial electrodes, contained within a custom-designed 
epicardial multielectrode with 128 bipoles. Additionally, a transvenous pacing lead was 
screwed into the interatdal septum. Four electrodes located in the high and low right 
(HRA/LRA) and left atrium (HLNLLA) were selected for multisita stimulation. Constant 
pacing at a CL 30 ms below sinus rate was applied from the following pacing sita(s) in 
random order: 1) HRA, 2) HRA + LRA, 3) HRA + LLA, 4) HRA + LRA + LLA, 5) HRA + 
LRA + HLA + LLA, and 6) septaL Number and duration of AF episodes with or without 
preventive pacing were studied during 10 rain intervals, separated by 5 min pauses, 
respectively. 
Results: The efficacy in suppressing AF increased with the number of pacing sites. Sin- 
gle-site septal pacing was as efficient as quadruple-site pacing. The data are summa- 
rized in the table below (*=p<0.05 vs. HRA; Tukey Kramer HSD test). 
Conclusion: In this expedmental model, preventive atrial pacing reduced the number of 
AF episodes, most efficiently with an increasing number of simultaneously paced sites or 
with a sin.91e pacing site located septally. 
Pacing sita(s) AF episodes (n) Episode duration (s) 
HRA 14.3±10.2 24±38 
HRA+LRA 7.5±8.3 22±27 
HRA+LLA 8.4±7.4 19±52 
HRA+LRA+LLA 7.1±6.5 12±19 
HRA+LRA+HLA+LLA 3.9±4.2* 37±81 
Septal 3.7±3.6* 37±75 
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1066-103 Left  Atr ia l  Appendage L igat lon  Dur ing Mltral  Valve 
Surgery  May  Increase the Risk of Late Thromboembolic 
Events 
Nour M. Juratli, Bruce L. Wilkoff, Patrick J. Tchou, Delos M Cosgrove, Bruce W. Lytle, 
Mina K. Chung, Michael S. Lauer, Luther T. Clark, Mark J. Niebauer, Walid Saliba, Robert 
A. Schweikert, Andrea Natale, Cleveland Clinic Foundation, Cleveland, Ohio. 
Background: The need for non-pharmacological treatment o prevent thromboembolic 
events (TEl in atrial fibrillation (AF) is increasing. Left atrial appendage (LAA) ligation 
during mitrat valve (MV) surgery was suggested as an alternative treatment to anticoagu- 
lation with warfarin, but the role of this surgical procedure is still controversial. Methods: 
Between 5/93 and 11/98 136 patients (pts) underwent LAA ligation during MV surgery. 
Complete follow up was available on 114 pts, There were 67 (58.8%) females and 47 
(41.2%) males with a mean age of 61.1 + 12.3 yrs and a mean LVEF of 46.7 ± 12.3%. 
The MV was replaced with bioprosthetic valve in 36 (31.6%) pts or mechanical in 27 
(23.7%) pts and repaired in 51 (44.7%) pts. A control group of 146 pts who underwent 
MV surgery without LAA ligation were selected randomly and found to match for age, 
sex, LVEF, type of valve surgery, left atrial size, HTN, DM, and smoking history. Late TE 
was defined as stroke, transient ischemic attack, or peripheral embolism occurring 48 
hours after the surgery. Cardiothoracic surgery database and telephone contact were 
used to assess the incidence of late TE. Results: Over a follow up period of 1318 + 481 
days 14 (12.3%) pts had TE in LAA ligation group vs 9 (6.2%) pts in the control group 
over a follow up penod of 1705 ± 650 days. Late TE by Kaplan-Meier curves for the two 
groups differed significantly for the entire follow up pedod with a p value of 0.034. The 
one year rate of TE in LAA ligation group was 8.8 ± 2.7% vs. 2.7 ± 1.4% in the control 
group. No warfarin therapy or subtherapeutic anticoagulation was found in 23 pts out of 
24 pts during TE. Among pts who were not prescribed warfadn prior to discharge home 
6/40 (15%) pts had TE in I.AA ligation group compared to 2/60 (3.3%) in the control 
group (p=0.023). There was no difference in late TE between the two groups among 
patients who were prescribed warfarin prior to discharge home 7/67 (11.5%) pts in LAA 
ligation group vs. 7/70 (10%) in control group (p=0.66). Conclusion: In this group of 
patients LAA tigation does not provide adequate protection from late thromboembolic 
events in the absence of effective anticoagulation with warfarin. 
1066-104 Prevent ion  of  Post -Cardiac Surgery  Atr ia l  F ibr i l lat ion Is 
Not  Assoc ia ted  With Decrease in Post-Operative 
Stroke: Meta-Ana lys is  
Euoene Crystal. Stuart J. Connolly, Khaled Sleik, Trecy J. Ginger, Salim Yusuf, McMaster 
University Hamilton, Ontario, Canada, Green Lane Hospital, Auckland, New Zealand. 
Post-operative atrial fibdllation (POAF) has been associated with increased rate of post- 
operative stroke. However, it is far from certain that the POAF is an actual cause of post- 
cardiac surgery stroke, because other intra- and extra-cardiac sources of embolism are 
common. No study has convincingly demonstrated that a decrease in POAF prevents 
post-cardiac surgery stroke. Therefore, we performed meta-analysis of randomized con- 
trolled trials on POAF prevention by drugs (beta-blockers, sotalol and amiodarone) and 
pacing, with the end-point of in-hospital post-operative stroke. The identification of trials 
and data derivation were performed in accordance to Cochrane group methodology. 
Results. The data regarding stroke were available in 12 randomized control trials, with 
the total population of 2683 patients. Most of trials excluded patients with low left ventdc- 
ular ejection fraction and other groups at increased ped-operative risk. 1064 pts were 
randomized to amiodarone, 347 to sotalol, 1077 to other beta-blockers and 195 to the 
pacing or control treatment. The control groups received routine care, or placebo. The 
occurrence of POAF decreased significantly from 39% in control group to 25% in treat- 
ment group (OR 0.45, 95%CI 0.35, 057). The incidence of post-operative stroke was 
1.2% in control vs. 1.2% in intervention group (OR 0.94,95%CI 0.46, 1.92). 
Conclusion. The enrolled population had low risk of peri-operative stroke. In this meta- 
analysis, decrease in occurrence of POAF was not associated with change in the rate of 
post-operative stroke, although the power of this study was still insufficient to prove dif- 
ferences in range below 1%. 
1066-105 Predictors of Warfarin Use in Atrial Fibrillation: Insights 
From the FRACTAL Regist ry  
Matthew R. Reynolds, Mark E. Josephson, P. A. Friedman, T. Hadjis, R. Lemery, T. D. 
Bahnson, D. S. Cannom, Peter Zimetbaum, Beth Israel Deaconess Medical Canter, 
Boston, Massachusetts. 
Background: Warfarin is underused for stroke prevention in atrial fibrillation (AF). Previ- 
ous studies have shown that some stroke risk factors such as prior stroke or congestive 
heart failure (CHF) are predictive of warfarin use, while other stroke risk factors are not. 
Prior studies have lacked longitudinal observation, and little is known about whether anti- 
coagulation rates vary by physician specialty type. 
Methods: We analyzed warfarin use in 1005 subjects enrolled in the Fibrillation Registry 
Assessing Costs, Therapies, Adverse events, and Lifestyle (FRACTAL), an observational 
cohort study of new onset atrial fibrillation. Possible determinants of warfarin use at 
enrollment and 12 months later were evaluated using logistic regression. 
== 
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Results: Initially, 65% of subjects received warfadn, but only 49% were on warfarin at 12 
months. Hypertension, CHF, valvular heart disease and a rate control strategy were pre- 
dictors of initial warfarin use; age<55 years, female gender, and history of coronary artery 
or ulcer disease were negative predictors. Predictors of warfarin use at 12 months are 
shown in Table 1. Hypertension, ulcer disease, gender, and physician specialty were not 
predictive. The strongest predictor of warfarin use at 12 months was recurrence of AF. 
Conclusions: Predictors of warfadn use in AF patients include stroke risk factors and 
potential warfarin contraindications. In addition, AF recurrence is a potent predictor for 
warfarin use 12 months after initial diagnosis. 
Table 1. Predictors of warfarin use at 12 months 
Variable Odds ratio (95% CI) P value 
AF recurrence 2.27 (1.51-3.42) 0.0001 
Prior stroke/TIA 2.09 (1.15-3.79) 0.02 
CHF 1.89 (1.25-2.87) 0.003 
Valvular disease 1.78 (1.16-2.66) 0.008 
Age <55 0.49 (0.33-0.74) 0.0008 
1066-106 Compar i son  of  Transesophageal Echocardiography- 
Detected Thromboembolic Risk Markers in Patients 
With Chronic Atrial Fibrillation and Atrial Tachycardia 
According to the SPAF Clinical Risk Stratification: A 
Prospective Study 
Nadia Benyounes, Valdrie Rozenberg, Lydia Djaouti, Charles Smadja, Mohammed 
Khirredine, Ariel Cohen. Saint Antoine University Hospital and Medical School, Paris. 
The thromboembolic (TE) risk of atdal flutter and tachycardias (AFT) has been reported 
as lower than atrial fibrillation (AF). Current guidelines suggest the need for a similar anti- 
coagulant strategy in both groups, This attitude could be balanced by a risk stratification 
using SPAF clinical cdteria and TE echocardiographic markers, 
Objective : We sought to compare the frequency of TE risk markers in patients (Pts) with 
chronic AF and AFT according to the SPAF clinicat criteria for TE dsk stratification. 
Methods : As part of an ongoing prospective study, we evaluated 212 Pts in chronic AF 
and 77 Pts in AFT using transthoracic and transesophagaal echocardiography (TEE). Pts 
were divided into high (n=113 and 43, respectively) and moderate/low (n=99 and 34, 
respectively) SPAF clinical risk groups. The following parameters were evaluated : left 
atdal (LA) and LA appendage (LAA) areas, spontaneous echo contrast (SEC), LAA end 
diastolic emptying velocity (Vel), LA thrombus (Thr) and thoracic aorta atheroma (TAA). 
Results : The main results are summarized in the table 
Chronic AF High Chronic AF Moderate/ AFT High AFT Moderate/ 
risk (n=113) low risk (n=99) risk (n=43) low risk (n=34) 
Mean age 75 ± 11 63.1 _+ 11.5 70.9 + 14.2 63.7 ± 12.9 
(years) 
LA area (cm 2) 24.7 ± 6.3 24.3 ± 6.0 23.7 ± 7.2 22.3 ± 6.9 
LAA area (cm 2) 5.4 + 2.3 5.9 ± 2.6 5.8 ± 2.6 5.4 ± 2.4 
LAA Vel <_25 55 (50.9)* 32 (34.7) 9 (21.9) 8 (25.0) 
cm/s (n,%) 
LA SEC (n,%) 75 (73.5)* 60 (63,8) 18 (45.8) 12 (44.4) 
LAA Thr (n,%) 6 (5.3) 1 (1.0) 2 (4.6) 0 
TAA_> 4 mm 18(17.3) 10(10.4) 10(23.8) 4(13.3) 
(n,%) 
*p< 0.05, high risk AF vs high risk AFT ; ** p< 0.05, moderate/low AF vs moderate/low 
risk AFT. 
Conclusion : LATE risk markers are more frequent in high risk Pts with AE However, 
LA and LAA dilatation and TAA are equally frequent in both high risk Pts. AFT should be 
stratified using the SPAF cdteria, similarly to AF, to help the accurate anticoagulant strat- 
egy. 
1066-119 A Risk Profile for Stroke or Death in Atrial Fibrillation: 
The Framingham Heart Study 
Thomas J. Wane. Joseph M. Massaro, Ralph B. D'Agostino, Daniel Levy, Philip A. Wolf, 
William B. Kannel, Martin G. Larson, Ramachandran S, Vasan, Emelia J, Benjamin, 
Framingham Heart Study, Framingham, Massachusetts. 
BACKGROUND: Individuals with atrial fibrillation (AF) are at increased risk of both 
stroke and death. Risk factors for stroke in AF have been studied, but mainly in subjects 
enrolled in randomized trials. We developed a clinical risk profile, and examined whether 
it could stratify risk among individuals with AF in the community. 
METHODS: We studied 870 subjects (mean age 74, range 55 to 94 years, 46% women) 
from the original and offspring cohorts of the Framingham Heart Study who developed 
AF after 1960, Stepwise Cox proportional hazards models were used to examine clinical 
predictors (obtained from history, physical exam, or ECG) of stroke or death during 5 
years of follow up. Subjects who had a stroke or died within 30 days of AF diagnosis 
were excluded. 
RESULTS: The 5-year event rate was 49%. The following predictors were significant in 
multivariable models: age, systolic blood pressure, smoking, prior myocardial infarction 
or heart failure, and heart murmur. Men in the lowest decile of predicted dsk had a 5-year 
event rate of 9.4%, while those in the highest decile had an event rate of 83.9%. The cor- 
responding values for women were 30.4% and 93.5%. Sex-specific predicted event rates 
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for a representat ive  70 year  old are  shown (Figure). 
CONCLUSION: Using a risk prediction model, it is possible to identify subjects with AF 
who are at particularly high or low risk of stroke or death, 
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1066-120 Embolic Event Rates After Direct Current Csrdioversion 
in Patients With Atrial Fibrillation and Ineffective 
Anticoagulation: Results of the Ludwlgshsfen 
Observational Atrial Fibrillation Study 
Karlheinz Seidl, Monika Rameken. Margit Vater, Harald Schwacke, Andreas Brandt, 
Caroline Bergmeier, Rail Zahn, Jochen Senges, Heart Center, Ludwigshafen, Germany. 
The Ludwigshafen atrial fibrillation (AF) study is a prospective single center observational 
study on an intention to cardiovert basis, including 1269 consecutive unselected patients 
(pts) with AF. Aim of this substudy was to evaluate the embolic event rate in pts with AF 
and ineffective anticoagulation (IA), in whom electrical cardioversion (CV) was intended. 
IA was defined, if warfarin was given, however INR was < 2, or if no anticoagulation was 
performed. Reasons for performing CV in pts with IA were AF of < 48 h, hemodynamic 
instable AF, or contraindication for anticoagulation. After cardioversion an overlap of war- 
farin therapy and intravenous hepadn was given to maintain adequate anticoagulation 
after CV in pts without contraindications for anticoagulation, 
Results: In 193 pts (15%) anticoagulation therapy was ineffective at the time of the 
intended CV. Transesophageal echocardiography (TEE) was performed in 126 pts, in the 
remaining 67 pts transthoracic echo was performed, A thrombus was found in 10 pts 
(7.9%) of the 126 pts with AF and ineffective anticoagulation. In 53 of the 126 pts (42%) 
TEE revealed spontaneous echo contrast. The grade of spontaneous echo contrast was 
mild in 74%, moderate in 19% and severe in 9%. In 150 of the 196 pts (78%) CV was 
performed, in the remaining 43 pts no CV was performed. In 2 of 150 pts (1.3%) with AF 
and IA a transient ischemic attack occurred in the first 4 weeks after CV. In both pts TEE 
was performed before CV, none of the pts had evidence of left atdal thrombus. In none of 
the 43 pts without CV a thromboembolic omplication occurred. In comparison the rate of 
thromboembolic omplications in the first 4 weeks after CV was 0.8 % (9/1076 pts) in pts 
with AF and effective anticoagulation at least 3 weeks prior to CV. 
Conclusion: 1) In our AF outpatient clinic 15% of the pts with AF had ineffective antico- 
agulation prior to CV. 2) The rate of embolic events in the first 4 weeks after the intended 
CV was 1.3 in pts with ineffective anticoagulation compared to 0.8 in pts with effective 
anticoagulation. 
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1067-107 Changes  in R-R Intervals During Ventricular 
Tachyarrhythmia Storms in Patients With Implantable 
Cardioverter-Defibrillator 
Xiaohong Zhou, Vinod Sharma, Jodi L. KoehIer, Paul J. DeGroot, Walter H. Olson, 
Medtronic, Inc, Minneapolis, Minnesota. 
BACKGROUND: Ventricular tachyarrhythmia (VTNF) storms, defined as greater than or 
equal to 3 episodes within 24 hours, have been reported in patients with implantable car- 
dioverter-defibrillator (ICD). The study objective was to determine whether predisposition 
to VTNF storms could be assessed from changes in episode related cardiac cycle 
lengths. METHODS: ICD patients (n=220) with coronary artery disease were followed for 
6.9±3.6 months post-implant. Stored electrograms were retrospectively reviewed and all 
true VTNF episodes, each of which was successfully terminated, were identified. Two 
types of changes in mean R-R interval (R-R) were calculated: (1) Delta-RR1, {[(mean R- 
R immediately prior to an episode)-(baseline mean R-R)]/(baseline mean R-R)}*100%, 
and (2) Delta-RR2, ([(mean R-R immediately after an episode)-(mean R-R immediately 
prior to an episode)]/(mean R-R immediately prior to an episode)}*100%. Baseline mean 
R-R was obtained at office visit and the mean R-Rs immediately prior to and immediately 
after an episode were obtained from ICD electrograms (excluding premature contrac- 
tion). RESULTS: There were a total of 629 episodes in 72 patients. Forty-one patients 
had all discrete episodes (total 91 episodes, group 1) without storms. Thirty-one patients 
experienced at least one storm and had a total of 538 episodes (group 2). Of 538 epi- 
sodes in group 2, 405 episodes (75%, group 2a) occurred in 57 storms and the remaining 
133 episodes were discrete (25%, group 2b). Each VTNF storm consisted of 7.1±5.7 
episodes (median = 5). The Delta-RR1 was -10.7±23.6% for group 1 and -27.3±15.4% 
